Metabolic syndrome among people living with HIV in Ethiopia: a systematic review and meta-analysis.
Ethiopia
HIV/AIDS
Meta analysis
Metabolic syndrome
Journal
Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958
Informations de publication
Date de publication:
28 Mar 2023
28 Mar 2023
Historique:
received:
03
12
2022
accepted:
18
03
2023
medline:
29
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
epublish
Résumé
Human Immuno-deficiency Virus (HIV) infection and antiretroviral therapy (ART) can cause metabolic disorders such as lipodystrophy, dyslipidemia, and insulin resistance, all of which are symptoms of metabolic syndrome (MetS). In Ethiopia, despite the existence of the primary studies, there was no pooled study conducted to summarize the country-level MetS among people living with HIV (PLHIV). Therefore, this study aims to estimate the pooled prevalence of MetS among PLHIV in Ethiopia. A systematic search was conducted to retrieve studies on the prevalence of MetS among PLHIV in Ethiopia from PubMed, Google Scholar, Science Direct, Web of Sciences, HINARI, and other relevant sources. A random-effects model was used to estimate the MetS in this study. The overall variation between studies was checked by the heterogeneity test (I Overall, 366 articles were identified and evaluated using the PRISMA guidelines, with 10 studies meeting the inclusion criteria included in the final analysis. The pooled prevalence of MetS among PLHIV in Ethiopia was 21.7% (95% CI:19.36-24.04) using National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) and 29.91% (95% CI: 21.54-38.28) using International Diabetes Federation (IDF) criteria. The lowest and highest prevalence of MetS were 19.14% (95%CI: 15.63-22.64) and 25.6% (95%CI: 20.18-31.08) at Southern Nation and Nationality People Region (SNNPR) and Addis Ababa, respectively. There was no statistical evidence of publication bias in both NCEP-ATP III and IDF pooled estimates. MetS was common among PLHIV in Ethiopia. Therefore, optimizing regular screening for MetS components and promoting a healthy lifestyle is suggested for PLHIV. Furthermore, more study is contributory to identify the barriers to implementing planned interventions and meeting recommended treatment goals. The review protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42023403786.
Sections du résumé
BACKGROUND
BACKGROUND
Human Immuno-deficiency Virus (HIV) infection and antiretroviral therapy (ART) can cause metabolic disorders such as lipodystrophy, dyslipidemia, and insulin resistance, all of which are symptoms of metabolic syndrome (MetS). In Ethiopia, despite the existence of the primary studies, there was no pooled study conducted to summarize the country-level MetS among people living with HIV (PLHIV). Therefore, this study aims to estimate the pooled prevalence of MetS among PLHIV in Ethiopia.
METHODS
METHODS
A systematic search was conducted to retrieve studies on the prevalence of MetS among PLHIV in Ethiopia from PubMed, Google Scholar, Science Direct, Web of Sciences, HINARI, and other relevant sources. A random-effects model was used to estimate the MetS in this study. The overall variation between studies was checked by the heterogeneity test (I
RESULTS
RESULTS
Overall, 366 articles were identified and evaluated using the PRISMA guidelines, with 10 studies meeting the inclusion criteria included in the final analysis. The pooled prevalence of MetS among PLHIV in Ethiopia was 21.7% (95% CI:19.36-24.04) using National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) and 29.91% (95% CI: 21.54-38.28) using International Diabetes Federation (IDF) criteria. The lowest and highest prevalence of MetS were 19.14% (95%CI: 15.63-22.64) and 25.6% (95%CI: 20.18-31.08) at Southern Nation and Nationality People Region (SNNPR) and Addis Ababa, respectively. There was no statistical evidence of publication bias in both NCEP-ATP III and IDF pooled estimates.
CONCLUSION
CONCLUSIONS
MetS was common among PLHIV in Ethiopia. Therefore, optimizing regular screening for MetS components and promoting a healthy lifestyle is suggested for PLHIV. Furthermore, more study is contributory to identify the barriers to implementing planned interventions and meeting recommended treatment goals.
TRIAL REGISTRATION
BACKGROUND
The review protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42023403786.
Identifiants
pubmed: 36978109
doi: 10.1186/s13098-023-01034-9
pii: 10.1186/s13098-023-01034-9
pmc: PMC10045608
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
61Informations de copyright
© 2023. The Author(s).
Références
Diabetol Metab Syndr. 2018 Feb 21;10:10
pubmed: 29483948
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Curr Hypertens Rep. 2016 Jun;18(6):46
pubmed: 27131801
Diabetes Metab Syndr. 2019 Sep - Oct;13(5):2833-2841
pubmed: 31425944
HIV Med. 2022 Mar;23(3):274-286
pubmed: 34816562
HIV Clin Trials. 2017 May;18(3):110-117
pubmed: 28420298
Diabetes Metab Syndr. 2014 Apr-Jun;8(2):102-7
pubmed: 24907175
J Obes. 2020 Dec 16;2020:2701309
pubmed: 33489358
J Family Med Prim Care. 2020 Mar 26;9(3):1550-1554
pubmed: 32509648
PLoS One. 2021 Jun 2;16(6):e0252320
pubmed: 34077481
Clin Med Insights Endocrinol Diabetes. 2022 Feb 24;15:11795514221078029
pubmed: 35237088
Lancet. 2008 Jul 26;372(9635):293-9
pubmed: 18657708
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Circulation. 2005 Nov 15;112(20):3066-72
pubmed: 16275870
BMC Res Notes. 2016 Mar 05;9:145
pubmed: 26945987
HIV AIDS (Auckl). 2022 Jun 17;14:297-309
pubmed: 35747268
Syst Rev. 2019 Jan 3;8(1):4
pubmed: 30606249
Medicine (Baltimore). 2020 Jul 2;99(27):e20845
pubmed: 32629671
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Pan Afr Med J. 2012;13:43
pubmed: 23330034
Medicina (Kaunas). 2021 Jun 05;57(6):
pubmed: 34198775
Curr HIV/AIDS Rep. 2022 Apr;19(2):141-153
pubmed: 35299263
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
J Diabetes Metab Disord. 2020 Jun 09;19(2):1671-1683
pubmed: 33553042
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1551-1556
pubmed: 32947754
PLoS One. 2016 Mar 23;11(3):e0150970
pubmed: 27008536
J Am Coll Cardiol. 2015 Sep 1;66(9):1050-67
pubmed: 26314534
Arch Public Health. 2020 May 07;78:40
pubmed: 32399212
J Diabetes Metab Disord. 2021 May 09;20(1):1021-1031
pubmed: 34222097
Int J Cardiol. 2015 Nov 15;199:307-18
pubmed: 26241636